QUIDELORTHO CORP Deferred Foreign Income Tax Expense (Benefit)
QUIDELORTHO CORP (QDEL) reported Deferred Foreign Income Tax Expense (Benefit) of $4.40 million for the 12-month period ending 2025-12-28, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-19
- QUIDELORTHO CORP deferred foreign income tax expense (benefit) for fiscal 2025 was $4.40M, a 82.04% decline from fiscal 2024.
- QUIDELORTHO CORP deferred foreign income tax expense (benefit) for fiscal 2024 was $24.50M.
- QUIDELORTHO CORP deferred foreign income tax expense (benefit) for fiscal 2023 was -$9.40M.
- QUIDELORTHO CORP deferred foreign income tax expense (benefit) for fiscal 2023 was -$200.00K.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-28 | $4.40M 10-K · filed 2026-02-19 |
| 2024-12-29 | $24.50M 10-K · filed 2026-02-19 |
| 2023-12-31 | -$9.40M 10-K · filed 2026-02-19 |
| 2023-01-01 | -$200.00K 10-K · filed 2025-02-27 |
| 2022-01-02 | -$2.00M 10-K/A · filed 2024-08-01 |
| 2021-01-03 | -$300.00K 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |